# US 11,027,009 B2 · Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,027,009 B2 - Document ID: US11027009B2 - Status: Granted - Kind: B2 - Application number: 16/872,785 - Filed: 2020-05-12 - Published: 2020-08-27 - Granted: 2021-06-08 - Earliest claimed: 2008-04-04 - Assignees: The Trustees of the University of Pennsylvania - Applicants: The Trustees of the University of Pennsylvania - Inventors: David B. Weiner; Matthew Morrow - Web page: https://patentgrep.com/patent/US11027009B2 ## CPC - A61K 39/285: Vaccinia virus or variola virus - A61K 38/20: Interleukins [IL] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 31/10: Antimycotics - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - A61P 31/16: for influenza or rhinoviruses - A61P 31/18: for HIV - A61P 31/20: for DNA viruses - A61P 31/22: for herpes viruses - A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis - A61P 35/00: Antineoplastic agents - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C07K 14/54: Interleukins [IL] - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed. ## Claims ### Claim 1 An immunogenic pharmaceutical composition comprising: an isolated nucleic acid molecule that encodes an immunogen, wherein the immunogen is a viral protein, and wherein the nucleic acid molecule further comprises a nucleotide sequence that encodes an IgE signal peptide; and an isolated nucleic acid molecule that encodes IL-28 or functional fragments thereof. ### Claim 2 (depends on 1) The immunogenic pharmaceutical composition of claim 1, wherein the nucleic acid molecules are plasmids. ### Claim 3 (depends on 1) The immunogenic pharmaceutical composition of claim 1, wherein the viral protein is from a virus selected from the group consisting of influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus, and hepatitis B virus. ### Claim 4 (depends on 3) The immunogenic pharmaceutical composition of claim 3, wherein the viral protein is from an influenza virus. ### Claim 5 An immunogenic pharmaceutical composition comprising an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunogen; a nucleotide sequence that encodes an IgE signal peptide; and a nucleotide sequence that encodes IL-28 or a functional fragment thereof, wherein the immunogen is a viral protein. ### Claim 6 (depends on 5) The immunogenic pharmaceutical composition of claim 5, wherein the nucleic acid molecule is a plasmid. ### Claim 7 (depends on 5) The immunogenic pharmaceutical composition of claim 5, wherein the viral protein is from a virus selected from the group consisting of influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus, and hepatitis B virus. ### Claim 8 (depends on 7) The immunogenic pharmaceutical composition of claim 7, wherein the viral protein is from an influenza virus. ### Claim 9 (depends on 1) An injectable immunogenic pharmaceutical composition comprising the immunogenic pharmaceutical composition of claim 1. ### Claim 10 (depends on 1) A method of inducing an immune response in an individual against an immunogen comprising administering to said individual an immunogenic pharmaceutical composition of claim 1. ### Claim 11 (depends on 5) A method of inducing an immune response in an individual against an immunogen comprising administering to said individual an immunogenic pharmaceutical composition of claim 5. ### Claim 12 A recombinant vaccine comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements, a nucleotide sequence that encodes an IgE signal peptide, and a nucleotide sequence that encodes IL-28 or a functional fragment thereof, wherein the immunogen is a viral protein. ### Claim 13 (depends on 12) The recombinant vaccine of claim 12, wherein the viral protein is from a virus selected from the group consisting of influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus, and hepatitis B virus. ### Claim 14 (depends on 13) The recombinant vaccine of claim 13, wherein the viral protein is from an influenza virus. ### Claim 15 (depends on 14) The recombinant vaccine of claim 14, wherein the recombinant vaccine is a recombinant vaccinia vaccine. ### Claim 16 (depends on 12) A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a recombinant vaccine of claim 12.